Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with Alvogen Korea to commercialize its serplulimab injection, HANSIZHUANG, in South Korea. This agreement grants Alvogen Korea exclusive rights to market the drug for various cancers, potentially enhancing Henlius’s market presence in Asia and providing significant financial milestones and royalties.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and commercialization of biologic drugs. The company specializes in creating therapies for cancer treatment, with a market focus on innovative biologics for oncology.
YTD Price Performance: 64.35%
Average Trading Volume: 1,626,880
Technical Sentiment Signal: Sell
Current Market Cap: HK$21.17B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue